Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | TDO2 | P48775 | 3/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20145485 | 1.00 | GBA1 (0.36) | GBA1IDO1TDO2CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL31226763 | 0.98 | IDO1 (0.39) | GBA1IDO1TDO2CHRNB4CHRNA3 | |
| SCHEMBL1728961 | 0.84 | IDO1 (0.42) | GBA1IDO1TDO2ADRB2PDE2A | |
| SCHEMBL557913 | 0.84 | IDO1 (0.42) | GBA1IDO1TDO2ADRB2PDE2A | |
| SCHEMBL4826929 | 0.84 | ADRB2 (0.39) | IDO1TDO2ADRB2GABRA1GABRB1 | |
| SCHEMBL4837352 | 0.84 | ADRB2 (0.39) | IDO1TDO2ADRB2GABRA1GABRB1 | |
| SCHEMBL1004099 | 0.84 | IDO1 (0.42) | GBA1IDO1TDO2ADRB2PDE2A | |
| SCHEMBL4826922 | 0.84 | ADRB2 (0.39) | IDO1TDO2ADRB2GABRA1GABRB1 | |
| SCHEMBL12263051 | 0.82 | GABRA1 (0.38) | IDO1TDO2CHRNB4CHRNA3GABRA1 | |
| Hydrochloric Acid SCHEMBL1876903 | 0.81 | IDO1 (0.45) | GBA1IDO1TDO2ADRB2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039892-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2269989-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039892-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | GBA1 3474/4885IDO1 62/4885TDO2 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.